Progress of new drugs on relapsed/refractory peripheral T-cell lymphoma
10.3760/cma.j.cn371439-20200507-00029
- VernacularTitle:复发/难治外周T细胞淋巴瘤的新药治疗进展
- Author:
Ke ZHAO
1
;
Huaqing WANG
Author Information
1. 天津市人民医院肿瘤诊治中心 天津市中西医结合肿瘤研究所 300121
- From:
Journal of International Oncology
2020;47(6):321-326
- CountryChina
- Language:Chinese
-
Abstract:
Peripheral T-cell lymphomas (PTCLs) are a group of heterogeneous diseases originating from post-thymic T-cells, with poor prognosis using traditional therapy, especially in patients with relapsed/refractory PTCLs (r/rPTCLs). In recent years, a variety of new anti-tumor drugs have emerged in the treatment of r/rPTCLs, including different types of enzyme inhibitors, monoclonal antibodies, immunomodulators and immune checkpoint inhibitors, which have been proved to be effective. The discovery and clinical application of new drugs are expected to improve the outcomes of the diseases.
